VITL

NASDAQ · Food Products

Vital Farms Inc

Small-Cap Stocks

$14.18

+0.53 (+3.88%)

As of May 9, 1:37 AM ET ·

VITL News1 articles

Bayer's $2.45B Perfuse Buy Aims to Revitalize Eye Drug Pipeline

Bayer acquires Perfuse Therapeutics for up to $2.45 billion to secure Phase II eye drug PER-001, aiming to bolster its ophthalmology unit as Eylea sales slip.